Want to see PRQR full AI Analyst Report?
PRQR Stock Chart & Stats
$2.38
$0.01(0.58%)
At close: 4:00 PM EDT
$2.38
$0.01(0.58%)
Day’s Range― - ―
52-Week Range$1.30 - $3.10
Previous Close$1.7
Volume683.10K
Average Volume (3M)759.98K
Market Cap
$194.75M
Enterprise Value$85.70M
Total Cash (Recent Filing)$117.08M
Total Debt (Recent Filing)$13.19M
Price to Earnings (P/E)―
Beta2.38
Next Earnings
Nov 05, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding141,121,480
10 Day Avg. Volume922,380
30 Day Avg. Volume759,984
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)3.12
Price to Sales (P/S)11.85
P/FCF Ratio-3.37
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue4.61
Enterprise Value/Gross Profit5.00
Enterprise Value/Ebitda-2.91
Forecast
1Y Price Target
$8.25Price Target Upside246.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$16.70M
Bulls Say, Bears Say
Bulls Say
AI-enabled Platform ExpansionEmbedding AI leadership into the Axiomer platform could improve discovery efficiency and create a repeatable development engine across programs. The reported AX-0811 advance and planned data readouts suggest this capability may support broader pipeline productivity over the next several quarters.
Clinical Pipeline AdvancementMoving multiple RNA-editing candidates into human testing is an important de-risking step for a development-stage biotechnology company. Clinical target-engagement data and expansion across liver and rare-disease programs could strengthen the platform’s scientific credibility and partnering potential.
Cash Runway And Manageable LeverageA substantial cash balance and runway into mid-2028 provide time to generate clinical evidence without immediate dependence on additional financing. Low leverage also preserves flexibility for research investment, although continued development spending remains necessary to realize the pipeline’s value.
Bears Say
Persistent UnprofitabilityThe company remains far from break-even despite improved revenue and high gross margins. Persistent operating losses reduce the ability to self-fund research, increase dependence on capital or partners, and could pressure the equity base if the development cycle remains lengthy.
Significant Cash BurnDeeply negative operating and free cash flow show that current activities consume substantial capital rather than generate it. Continued burn can shorten the effective runway, constrain development choices, and make future financing needs more important even with the reported cash balance.
Reliance On Collaborations And LicensingA collaboration-led revenue model can be uneven because payments depend on agreements, research funding, milestones, and eventual royalties. Without marketed products, ProQR lacks recurring commercial sales to offset R&D costs, leaving financial progress tied to partners and program events.
ProQR News
PRQR FAQ
What was ProQR’s price range in the past 12 months?
ProQR lowest stock price was $1.30 and its highest was $3.10 in the past 12 months.
What is ProQR’s market cap?
ProQR’s market cap is $194.75M.
When is ProQR’s upcoming earnings report date?
ProQR’s upcoming earnings report date is Nov 05, 2026 which is in 14 days.
How were ProQR’s earnings last quarter?
ProQR released its earnings results on Aug 13, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.128 by $0.038.
Is ProQR overvalued?
According to Wall Street analysts ProQR’s price is currently Undervalued.
Does ProQR pay dividends?
ProQR does not currently pay dividends.
What is ProQR’s EPS estimate?
ProQR’s EPS estimate is -0.11.
How many shares outstanding does ProQR have?
ProQR has 141,121,480 shares outstanding.
What happened to ProQR’s price movement after its last earnings report?
ProQR reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.128. Following the earnings report the stock price went down -0.538%.
Which hedge fund is a major shareholder of ProQR?
Currently, no hedge funds are holding shares in PRQR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProQR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.25 (246.64% Upside)
$8.25 (246.64% Upside)
Blogger Sentiment
Bullish
PRQR Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $608.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.75%
12-Months-Change
Fundamentals
Return on Equity
-68.44%
Trailing 12-Months
Asset Growth
-5.42%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ProQR
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
PRQR Stock 12 Month Forecast
Average Price Target
$8.25
▲(246.64% Upside)
Technical Analysis
Ownership Overview
0.57% Insiders
1.38% Mutual Funds
0.13% Other Institutional Investors
97.65% Public Companies and
Individual Investors